ArticleScientific reports2025
Elevated FDP levels independently predict poor outcomes in HBV-ACLF patients treated with artificial liver support system therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction · 2026-02-23Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Data · Investigation by Journal/Publisher · Lack of Approval from Third Party ·
- Retracted
Authors and funding
5 authors.
Funding
Abstract
Acute-on-chronic liver failure (ACLF) is an extremely severe clinical syndrome, often associated with systemic inflammation, coagulation dysfunction, and fibrinolysis abnormalities. Fibrin degradation product (FDP), as a byproduct of fibrinolysis, is a crucial indicator reflecting the state of fibrinolysis. The objective of this study is to investigate the relationship between FDP levels and the 28-day mortality rate in patients with ACLF. We retrospectively enrolled 520 patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) who underwent artificial liver support system therapy and collected relevant clinical data at admission. Cox regression analysis was employed to investigate the relationship between FDP levels and the 28-day mortality rate, and the predictive value of FDP was evaluated using receiver operating characteristic (ROC) curves. Among the 520 eligible patients, the 28-day mortality rate was 20.2%. The FDP levels of surviving patients were significantly lower than those of deceased patients [6.15 (3.23-10.97) vs. 16.98 (9.58-28.93), P < 0.001]. Through multivariate Cox proportional hazards analysis, after adjusting for confounding factors, It was observed that for every 10 µg/mL increase in FDP levels, the risk increased by 12.8% [HR = 1.128 (95% CI: 1.044-1.219), P < 0.001]. Compared to patients with low FDP levels (< 11.1 µg/mL), patients with high FDP levels (≥ 11.1 µg/mL) demonstrated a markedly higher mortality risk [HR = 3.222 (95% CI: 1.999-5.192), P < 0.001]. Among various prognostic scores, the COSSH-ACLF score exhibited the largest area under the receiver operating characteristic curve (AUROC), comparable to that of FDP (P = 0.891), and its predictive performance was superior to that of FIB and D-dimer. Additionally, for patients who received three or more sessions of artificial liver support system therapy, those with high FDP levels had a significantly reduced 28-day mortality risk. Elevated FDP levels are associated with the 28-day prognosis in patients with HBV-ACLF. Moreover, undergoing multiple sessions of artificial liver treatment is associated with favorable survival outcomes for patients with high FDP levels (≥ 11.1 µg/mL).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.